The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

The efficacy of afatinib in combination with bevacizumab in untreated advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma is currently unclear. We sought to investigate the efficacy of this combination through a multicenter observational analysis. Data for 57 patients with a...

Full description

Bibliographic Details
Main Authors: Ping-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, Scott Chih-Hsi Kuo, Chia-Hsun Chu, Pi-Hung Tung, Allen Chung-Cheng Huang, Chih-Liang Wang, Li-Chung Chiu, Yueh-Fu Fang, Cheng-Ta Yang
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceuticals
Subjects:
afatinib
bevacizumab
anti-angiogenesis
epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI)
lung adenocarcinoma
Online Access:https://www.mdpi.com/1424-8247/13/11/331

Internet

https://www.mdpi.com/1424-8247/13/11/331

Similar Items